🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT06875336
Recruiting Observational

A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tuberculosis

NCT06875336 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2023-03-06
Last updated
2025-03-13

Condition(s) studied

Extrapulmonary Tuberculosis

Investigational drug(s) / intervention(s)

biomarker analysis

biomarker analysis: PAXgene blood for RNA will be collected and stored. Results from these additional examinations are not included in the treatment monitoring of the patient concerned. If M. tuberculosis can be cultivated, strains will be stored for genotyping and whole genome sequencing. Serum biomarkers will be tested using commercially available kits. In addition, TAM-TB assays will be performed from samples stored at each time-point. For this purpose, PBMCs will be collected and frozen using well-established protocols.

Study summary

This is a prospective, multicenter, observational study (mEX-TB study) of patients with extrapulmonary tuberculosis (EPTB). Adult patients newly diagnosed with EPTB will prospectively be enrolled into the study. Clinical data will be collected using standardized questionnaires over the whole treatment period for each individual. Additionally, body fluids (blood, urine) will be collected and stored in a central biobank. Biomarkers in EPTB patients will be analyzed during the course of therapy and correlated with clinical data. In addition, a healthy control group will be added, to be used primarily as technical controls for complex laboratory procedures such as RNA-seq and T-cell based assays.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years 2. Isolation of Mycobacterium tuberculosis complex from a bodily secretion or tissue by 1. PCR 2. culture or a presumptive clinical diagnosis based on epidemiologic exposure in combination with physical findings, radiographic findings and/or histopathology 3. Patients with extrapulmonary TB * pleura * lymph nodes * bones and joints * larynx * pericardial * parotid gland * abdominal sites * kidneys * genitourinary tract * disseminated (miliary) TB * other than pulmonary TB 4. In the case of pulmonary and extrapulmonary involvement, the leading manifestation, clinically and radiographically, must be extrapulmonary. 5. Written informed consent provided prior to inclusion Exclusion Criteria: * 1\. Age \<18 years 2. Patient with any social or logistical condition which, as anticipated by the investigator, may interfere with the conduct of the study, such as incapacity to well understand the study content and procedure (in case of any language barriers, a translator may be involved), not willing to collaborate, or anticipated inability to finish study due to physical weakness 3. Dependencies towards the study team (e.g. family members, employees of the same department) 4. Pregnant women 5. Patient in custodianship or guardianship 6. Leading pulmonary manifestation 7. Solitary CNS tuberculosis Patients may take part in other clinical studies and trials, as long as there is no conflict with the inclusion or exclusion criteria of the mEX-TB study and the protocol of the other study or trial does not conflict with the means of data and sample collection and publication of this protocol.

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
University Hospital Bonn Bonn Germany Not Yet Recruiting
Research Center Borstel Borstel Germany Recruiting
University Hospital of Cologne Cologne Germany Recruiting
University Hospital Frankfurt Frankfurt Germany Not Yet Recruiting
University Hospital Hamburg Hamburg Germany Recruiting
University Hospital Heidelberg Heidelberg Germany Recruiting

More University of Cologne trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06875336 on ClinicalTrials.gov ↗ ← All trials in Germany